Why do people develop antibodies to food? While clinicians have long observed that healthy humans develop a particular type ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Otsuka's experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new ...

Otsuka's investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with ...

Bound IgG were detected by a further 1-hour incubation ... The assay was then continued as a direct binding assay. HCMV UL94 protein production. The UL94 coding region was cloned in the expression ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

† Department of Pharmacology, School of Medicine, University of Colorado Denver, Aurora, Colorado, United States ‡ Molecular Toxicology and Environmental Health Sciences Program, Department of ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

Members of the B-cell lymphoma 2 (BCL-2) protein family have pro- or anti-apoptotic activities and have been studied intensively over the past decade for their importance in regulating apoptosis, ...